Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Amarin Corporation plc (ADR) (AMRN) News: Struggle, New Announcement & AstraZeneca Plc (AZN)’s Dominance

Editor’s Note: Related tickers: Amarin Corporation plc (ADR) (NASDAQ:AMRN), AstraZeneca plc (NYSE:AZN), Omthera Pharmaceuticals Inc (NASDAQ:OMTH)

Amarin Stays Rangebound, Prescriptions Stagnate (ProactiveInvestors)
Amarin Corporation plc (ADR) (NASDAQ:AMRN) has been struggling a lot lately as retail channel prescription data for its EPA capsule Vascepa imply that the drug is starting to slow down its momentum in the MARINE indication (hypertriglyceridemia patients with >500 mg/dL). While the company has seen significant progress since the launch of the drug in January, it is still not causing any excitement in an investor base that wanted to see a big pharma buyout of the company ever since the company reported successful Phase III results. Despite the incredible strength of the broader market and the biotech sector in particular this year, AMRN is down 14% YTD as of the time of writing.

Amarin Corporation plc (ADR) (NASDAQ:AMRN)

Big Pharma Wants Fish Oil After All, But At Half Amarin’s Selling Price (TheStreet)
Big Pharma is interested in prescription-grade fish oil after all. AstraZeneca plc (NYSE:AZN) is buying Omthera Pharmaceuticals Inc (NASDAQ:OMTH) in an incentive-laden deal worth up to $443 million. To buy Omthera Pharmaceuticals Inc (NASDAQ:OMTH), AstraZeneca plc (NYSE:AZN) passed over Amarin Corporation plc (ADR) (NASDAQ:AMRN) and its prescription-grade fish oil Vascepa. Perhaps Amarin will also find a Big Pharma buyer one day, except the market value for its only product has now been set at roughly half the company’s current $1 billion market valuation. Looks like Amarin Corporation plc (ADR) (NASDAQ:AMRN) can be bought for $4 per share. Any takers?

Amarin (AMRN) Sees Upside After AstraZeneca Scoops-Up Omthera (OMTH) (StreetInsider)
Amarin Corporation plc (ADR) (NASDAQ:AMRN) is seeing pre-open interest Tuesday after AstraZeneca plc (NYSE:AZN) acquired fellow fish oil pharmaceutical company Omthera Pharmaceuticals Inc (NASDAQ:OMTH) for as much as $443 million. While the comparable valuation of the deal is not viewed as positive for Amarin Corporation plc (ADR) (NASDAQ:AMRN), speculators suggest the deal activity puts the spotlight directly on Amarin. Shares of Amarin Corporation plc (ADR) (NASDAQ:AMRN) last traded at $7.05, up 4 percent.

Amarin Corporation plc (ADR) : Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy (4-Traders)
Amarin Corporation plc (ADR) (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s U.S. Patent Application Serial Number 13/417,899 titled “Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same.” This application includes claims intended to protect the Vascepa® (icosapent ethyl) indication approved by the U.S. Food and Drug Administration (FDA) based on Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s MARINE clinical trial results specifically those results seen in patients on statin therapy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!